Abstract
Background/Aims
Acute liver injury is a common manifestation of parvovirus B19 (PVB19) infection in immunocompromised patients. However, literature in immunocompetent children is scarce. We aimed to study the clinicolaboratory features and outcome of hepatic involvement by PVB19 infection in hospitalized children.
Methods
We retrospectively analyzed our prospectively kept database of all children (<18 years old) admitted with acute viral hepatitis (AVH), acute liver failure (ALF) or acute-on-chronic liver failure (ACLF), and PVB19 infection between January 2010 and December 2023. Clinical features, laboratory parameters, and complications were evaluated. Poor outcome was defined as death or liver transplantation.
Results
A total of 35 children (19 boys [54%], median age: 7.25 [interquartile range: 4–10.8] years) with PVB19-related hepatitis were studied (28 [80%] isolated PVB19 infection and 7 [20%] coinfections [3 with Epstein–Barr virus, 2 with hepatitis A, and 1 each with hepatitis-E and cytomegalovirus]). AVH (17, 49%) was the most common presentation, followed by ALF (13, 37%) and acute insult in ACLF (5, 14%). Patients with coinfection had significantly higher bilirubin (14.6 [9.4–21.5] vs 6.8 [4.3–10.9] mg/dl; P=0.004) and transaminases (ALT: 697 [428–1296] vs. 277 [157–478] U/L; P=0.02) but similar mortality (1/7 vs 6/23; P=1.0) than PVB19 alone. Nine cases (25.7%) had extrahepatic complications (hemophagocytic lymphohistiocytosis [HLH]: 3, acute kidney injury: 3, aplastic anemia: 2, and myocarditis: 1). Poor outcome occurred in 38% (5/13) ALF, 11.7% (2/17) AVH (HLH: 1, myocarditis: 1), and none (0/5) of the ACLF cases.
Conclusion
PVB19 should be considered in children presenting with indeterminate acute liver injury, especially in younger children or those with complications such as aplastic anemia, HLH, or myocarditis.
Keywords: parvovirus B19, hepatitis, children, aplastic anemia, hemophagocytic lymphohistiocytosis
Parvovirus B19 (PVB19) is a member of the Parvoviridae family of viruses that can infect erythroid precursors, hepatocytes, and other cells that possess globosides and glycosphingolipids in their cell membrane.1 PVB19 infection is globally prevalent, being more common among young children.1,2 PVB19 infection is transmitted mainly by respiratory droplets, and the disease often occurs in outbreaks among school-aged children.3 It has a varied clinical presentation, with erythema infectiosum being the most common in children.4 The illness usually starts with fever and nonspecific influenza-like symptoms followed by rash and rheumatic symptoms such as arthralgia or arthritis.4 Hepatic manifestations are under-recognized but not uncommon.5,6 PVB19 infection can cause acute viral hepatitis (AVH), which can progress to acute liver failure (ALF), and it can be the acute insult in children with chronic liver disease (CLD) leading to acute-on-chronic liver failure (ACLF).5, 6, 7, 8 However, pediatric literature is limited, mostly in the form of case reports/series, mainly in immunocompromised patients.9, 10, 11, 12, 13 Hence, we aimed to study the hepatic manifestations and outcome of PVB19-related hepatitis in children managed at our center.
Methods
Ethics Statement
Ethical clearance was taken from the Institute's Ethical Committee with exemption from informed consent as there was no direct contact with the patient [2023-303-IP-135 PGI/BE/30/2024]. The study conforms with the Helsinki Declaration of 1975, as revised in 2000 and 2008, concerning human and animal rights.
We retrospectively analyzed our prospectively kept database of all the children <18 years of age, who were admitted with acute liver injury (AVH, ALF, ACLF) between January 2010 and December 2023. Consecutive children admitted with a diagnosis of AVH or ALF or acute insult in ACLF due to PVB19 infection, fulfilling the inclusion criteria, were included in the study. ALF was defined as biochemical evidence of acute liver injury in a child with no known evidence of chronic liver disease along with at least one of the following: international normalized ratio (INR) >1.5, not corrected with vitamin K supplementation, with encephalopathy or INR >2.0, not corrected with vitamin K supplementation, without encephalopathy.14 ACLF was defined according to the Asia Pacific Association for the Study of the Liver criteria.15 Etiology of underlying CLD in ACLF was determined as per standard criteria.16, 17, 18 Diagnosis of AVH was based on clinical features: >3 times upper limit of normal increase in aminotransferases and positive viral serology/polymerase chain reaction (PCR) using commercial kits. The etiological agent for the acute liver injury was labeled as hepatitis A (immunoglobulin M [IgM] anti–hepatitis A virus [HAV] positive), hepatitis E (IgM anti–hepatitis E virus [HEV] positive), and hepatitis B (IgM anti-hepatitis B core [HBc] antibody with/without hepatitis B surface antigen [HBsAg] positive). Diagnosis of PVB19 infection was confirmed by the presence IgM antibodies against specific viral antigens by enzyme-linked immunosorbent assay [ELISA] (DRG Parvovirus B19 IgM Enzyme Immunoassay [EIA], DRG International Inc. USA and NovaLisa, Nova Tec Immunodiagnostica, GmBH). Epstein–Barr virus (EBV) infection was diagnosed if IgM antibody to viral capsid antigen of EBV (CHORUS platform [DIESSE Diagnostics, Italy]) was detected. Leukopenia was defined as a total leukocyte count of < 4000/mm3 and thrombocytopenia as platelet a count of <1,50,000/mm3. Acute kidney injury (AKI) was defined as per Kidney Disease: Improving Global Outcomes guidelines.19 Hemophagocytic lymphohistiocytosis (HLH),20 aplastic anemia (AA),21 and myocarditis22 were defined as per standard criteria.
All cases presenting with AVH or ALF or ACLF were tested for hepatotrophic viruses (HAV/HEV/hepatitis B virus [HBV]). Testing for atypical viruses (EBV, PVB19, cytomegalovirus, herpes simplex virus) was done either along with the hepatotrophic virus or sequentially in case of individuals who tested negative for the hepatotrophic virus panel as per the discretion of the treating physician.
All patients were treated as per standard treatment protocol.14,15 All cases were followed-up in the outpatient department till the resolution of clinical symptoms, regression of organomegaly, and normalization of liver function tests (LFTs) in those with AVH/ALF. Children with ACLF continued to be in follow-up and received therapy for the underlying CLD. All the data were retrieved from our electronic database (hospital information system) and physical case-record files and entered into prestructured proforma. Clinical and laboratory data, complications, the treatment given, and outcome were noted and analyzed. Poor outcome was defined as death or need of liver transplantation.
Statistical Analysis
Statistical analysis was performed using IBM SPSS statistical software version 20 (SPSS, Chicago, Illinois, USA). A P-value of <0.05 was considered statistically significant. Continuous variables were expressed as median with interquartile range (IQR) and discrete variables as proportions. Comparisons of continuous variables between two groups were done using the independent t-test and Mann–Whitney U-test as per normality of data distribution. Proportions were compared by Chi square test/Fishers exact test.
Results
A total of 35 children (19 boys [54%], median age: 7.25 [IQR: 4–10.87] years) were diagnosed to have PVB19-related acute liver injury (28 [80%] cases of isolated PVB19 infection and 7 [20%] of coinfection [EBV + PVB19-3 {8.5%}, HAV + PVB19-2{5.5%}, HEV + PVB19-1{2.8%}, cytomegalovirus + PVB19-1{2.8%}]). Among the 35 cases, 17 (49%) had presentation as AVH, 13 (37%) as ALF, and 5 (14%) as ACLF (underlying CLD being autoimmune hepatitis [AIH] type 1 in 3, Wilson disease [WD] in 1, Budd–Chiari syndrome [BCS] in 1). The age-group-wise distribution of cases with PVB19 infection is depicted in Figure 1. Of all the cases with PVB19, maximum were in the 2–5 y (n: 15/35, 42.8%) age group followed by 5–10 y (n: 11/35, 31.4%), 10–18 y (n: 7/35, 20%), and <2 y (n: 2/35, 5.7%). PVB19-related AVH constituted 4.4% (17/374) of all cases of AVH in our center during the study period. The prevalence of PVB19-related AVH was higher in children aged <5 years (9/102 [8.8%]) than in the older children (>5–18 years of age: 8/272 [2.9%]; P=0.03).
Figure 1.
Age-group-wise distribution of cases with parvovirus B19–related acute hepatitis.
Fourteen (40%) children had prodromal symptoms of fever, nausea, and vomiting, whereas 5 (14%) cases each had skin rashes and diarrhea. Of the 35 cases, 85% (n=30) had anemia, with a median hemoglobin of 8 gm/dL (IQR: 6.3–10.1) at presentation. We compared the clinical characteristics and laboratory parameters of 2 patient groups: acute hepatic injury (AVH and ALF) due to PVB19 alone vs coinfection of PVB19 with other hepatotropic viruses (Table 1). The clinical presentation was similar. Total and direct bilirubin, AST, and ALT values were significantly higher in the coinfection group than in the isolated PVB19 group, whereas serum total protein, albumin, INR, and hemoglobin levels were not different between the two groups.
Table 1.
Comparison of Clinical Features and Outcome of Acute Hepatic Injury (Acute Viral Hepatitis and Acute Liver Failure) due to Parvovirus B19 (PVB19) Alone vs PVB19 and Other Hepatotropic Virus Coinfection.
| Parameter | Isolated PVB19 infection (n = 23) | Coinfection of PVB19 and other hepatotropic virus (n = 7)a | P value |
|---|---|---|---|
| Presentation: | |||
| AVH | 13 (56.5%) | 4 (57%) | 0.96 |
| ALF | 10 (43.5%) | 3 (43%) | 0.98 |
| Age | 7.25 years (4–10.7) | 6 years (5–11.5) | 0.62 |
| Gender | |||
| Male:female | 16:12 | 3:4 | 0.52 |
| Prodromal symptoms | 10 (43.5%) | 4 (57%) | 0.66 |
| Ascites | 6 (26%) | 3 (43%) | 0.38 |
| Pedal edema | 2 (8%) | 1 (14%) | 0.63 |
| Hepatomegaly | 20 (87%) | 6 (85%) | 0.97 |
| Splenomegaly | 2 (9%) | 2 (28%) | 0.07 |
| Skin rashes | 5 (21%) | 1 (14%) | 0.68 |
| Diarrhea | 5 (21%) | 1 (14%) | 0.68 |
| Total bilirubin (mg/dL) | 6.8 (4.3–10.9) | 14.6 (9.4–21.5) | 0.004 |
| Direct bilirubin (mg/dL) | 3.9 (2.4–6.2) | 9.3 (5.7–14.3) | 0.003 |
| Aspartate aminotransferase (U/L) | 303 (133–518) | 567 (460–1140) | 0.04 |
| Alanine aminotransferase (U/L) | 277 (157–478) | 697 (428–1296) | 0.02 |
| Alkaline phosphatase (U/L) | 238 (188–276) | 324 (240–384) | 0.06 |
| Total protein (g/dL) | 5.3 (5–7.2) | 5.4 (5–6.7) | 0.39 |
| Albumin (g/dL) | 3.3 (3–3.7) | 3.15 (2.9–3.45) | 0.32 |
| INR | 2.32 (1.2–2.78) | 2.2 (1.2–2.9) | 0.52 |
| Hemoglobin (g/dL) | 7.8 (6.7–10.3) | 8.2 (6.8–9.8) | 0.95 |
| Total leukocyte count (/mm3) | 5800 (3200–8500) | 6500 (5500–10400) | 0.54 |
| Platelet (/mm3) | 187,000 (113,000–375,000) | 210,000 (185,000–340,000) | 0.19 |
| Corrected reticulocyte count (%) | 1.1 (0.5–1.2) | 1.1 (0.7–1.4) | 0.72 |
| Complications | |||
| Aplastic anemia | 2 (9%) | 0 (0%) | 0.76 |
| HLH | 2 (9%) | 1 (14%) [PVB19 + EBV] | 0.41 |
| AKI | 2 (9%) | 1 (14%) [PVB19 + HAV] | 0.76 |
| Myocarditis | 1 (4.5%) | 0 (0%) | 0.57 |
| Median follow-up durationb | 5.5 months (2–11) | 6.7 months (2–13.5) | 0.68 |
| Mortality | |||
| AVH | 2/13 (15%)c | 0/4 (0%) | 0.42 |
| ALF | 4/10 (40%) | 1/3 (33%) [PVB19+ HAV] | 0.83 |
Abbreviations: AVH = acute viral hepatitis, ALF = acute liver failure, INR = international normalized ratio, PVB19 = parvovirus B19, HLH = hemophagocytic lymphohistiocytosis, AKI = acute kidney injury, EBV = Epstein–Barr virus, HAV = hepatitis A virus.
Patients with ACLF were excluded from this analysis as the underlying CLD can affect the presentation, laboratory values, and outcome.
Continuous variables were expressed as median with interquartile range (IQR), and discrete variables were expressed as proportions.
Coinfection with hepatitis A virus (n=2), hepatitis E virus (n=1), Epstein–Barr virus (n=3), and cytomegalovirus (n=1).
For survivors.
Death due to nonhepatic causes (1 myocarditis, 1 HLH).
None of the children with AVH/ALF had history suggestive of or known immunodeficiency disorder, human immunodeficiency virus infection, underlying systemic diseases, or drug intake (immunosuppression/complementary and alternative medicine) and were healthy prior to this episode of jaundice. Among the 5 cases with ACLF, the child with BCS was diagnosed first time during this presentation. The other 4 children with ACLF (AIH: 3, WD: 1) were previously diagnosed and were on therapy prior to presentation as ACLF.
Complications
Nine cases (9/35, 25.7%) had complications of HLH (3, 8.5%), AKI (3, 8.5%), AA (2, 5.5%), and myocarditis (1, 3%), as shown in Table 2. There was no difference in the complications between the isolated PVB19 and the coinfection group (Table 1). Details of the complications are summarized in Table 2. Amongst the three cases of HLH, two received intravenous immunoglobulin (IVIG) and dexamethasone, and both recovered. The third child with HLH received IVIG, dexamethasone, and etoposide; however, she succumbed to infectious complications (pneumonia with septic shock). Of the three children with AKI, one had prerenal AKI and recovered with volume replacement, whereas the other two children had intrinsic AKI. Both required continuous renal replacement therapy (done in 1 case) and had a poor outcome.
Table 2.
Extrahepatic Complications in Patients with Parvovirus B19 (PVB19) Infection.
| Serial no | Age/gender | Infectious agent | Clinical presentation | Complication | Treatment | Outcome |
|---|---|---|---|---|---|---|
| 1 | 2.8 y/girl | Parvovirus | ALF | HLH | IVIG, dexamethasone | Recovered |
| 2 | 3 y/boy | Parvovirus | AVH | HLH | IVIG, Dexamethasone, etoposide | Death |
| 3 | 6 y/girl | Parvovirus + EBV | AVH | HLH | IVIG, dexamethasone | Recovered |
| 4 | 9 y/boy | Parvovirus | AVH | Aplastic anemia | G-CSF, Blood component transfusion, antithymocyte globulin | Recovered |
| 5 | 6.5 y/girl | Parvovirus | AVH | Aplastic anemia | G-CSF, blood component transfusion | Recovered |
| 6 | 4 y/boy | Parvovirus | AVH | Myocarditis | IVIG given | Death |
| 7 | 4 y/boy | Parvovirus | ALF | Intrinsic AKI | CRRT advised but not done | Death |
| 8 | 4 y/boy | Parvovirus | ALF | Pre-renal AKI | Volume replacement | Recovered |
| 9 | 5 y/girl | Parvovirus + hepatitis A virus | ALF | Intrinsic AKI | CRRT done | Death |
Abbreviations: y = years, AVH = acute viral hepatitis, ALF = acute liver failure, PBV19 = parvovirus B19, HLH = hemophagocytic lymphohistiocytosis, IVIG = intravenous immunoglobulin, CRRT = continuous renal replacement therapy, AKI = acute kidney injury, G-CSF = granulocyte colony-stimulating factor.
The two cases of AA were confirmed on bone marrow biopsy and treated (one with granulocyte-colony stimulating factor and another with anti-thymocyte globulin) in consultation with the hematologist, and both recovered. The child with PVB19-related myocarditis was given supportive treatment and IVIG in consultation with the cardiologist. However, he worsened despite treatment, developed pulmonary edema, and succumbed.
Outcome
Seven cases (7/35, 20%) had a poor outcome: 5/13 (38%) with ALF and 2/17 (11%) with AVH (Table 3). Amongst the AVH cases, both cases with poor outcome had nonhepatic complications (myocarditis with cardiogenic shock: 1 and HLH: 1). Rest, all cases of AVH recovered with complete normalization of LFT over a median follow-up period of 2.3 months (IQR: 1.1–4.2). In the ALF group, the mortality rate was 38% (n: 5). The remaining 8 (62%) children with ALF recovered completely over a median follow-up period of 4.7 months (IQR: 3–7.5). All children (n: 5) with ACLF improved and survived with their native liver. All 5 cases were given specific etiology-based therapy for the underlying CLD (d-penicillamine for Wilson disease [n: 1], prednisolone and immunomodulators [azathioprine: 2, mycophenolate mofetil: 1] for autoimmune hepatitis [n: 3], and right hepatic vein angioplasty with stenting for Budd–Chiari syndrome [n: 1]). None of them developed any PVB19-related complications and are in follow-up (8 [range: 6–10.5] months).
Table 3.
Details of the Patients with Parvovirus B19 (PVB19)-Related Hepatitis with Poor Outcome.
| Etiology | Presentation | Age/sex | Jaundice to HE interval | Grade of HE | Complications | Worst INR | Treatment given |
|---|---|---|---|---|---|---|---|
| PVB19 | ALF | 4 y/M | 20 days | Gr III | Cerebral edema, AKI | 4.7 | SMT, ventilation, CRRT advised but not done |
| PVB19 | ALF | 2.8 y/F | 14 days | Gr II | Pulmonary hemorrhage | 4.8 | SMT, ventilation |
| PVB19 | ALF | 7.5 y/F | 18 days | Gr II | SBP, pulmonary hemorrhage | 3.8 | SMT, ventilation |
| PVB19 | ALF | 4 y/F | 14 days | Gr III | Cerebral edema | 6.4 | SMT, ventilation, |
| PVB19 + hepatitis A infection | ALF | 5 y/F | 10 days | Gr III | Cerebral edema, AKI, refractory shock | 6.4 | SMT, ventilation, CRRT |
| PVB19 | AVH | 3 y/M | – | – | HLH | 1.3 | IVIG, dexamethasone etoposide |
| PVB19 | AVH | 4 y/M | – | – | Myocarditis, pulmonary edema with cardiogenic shock | 1.4 | Ventilation, IVIG |
Abbreviation: y = years, INR = international normalized ratio, AVH = acute viral hepatitis, ALF = acute liver failure, HE = hepatic encephalopathy, AKI = acute kidney injury, HLH = hemophagocytic lymphohistiocytosis, PVB19 = parvovirus B19, SBP = spontaneous bacterial peritonitis, SMT = standard medical treatment for ALF, IVIG = intravenous immunoglobulin, CRRT = continuous renal replacement therapy, M = male; F = female.
Discussion
PVB19 constituted 4.4% of all AVH23 and 4.7% of ALF [unpublished data] cases at our center between 2010 and 2023. The prevalence of PVB19-related AVH was significantly higher in the under-five children. AVH (49%) and ALF (37%) were the most common presentation of PVB19-related hepatitis, whereas it was found to be the acute insult in 5 cases of ACLF. The majority (28, 80%) of the cases had isolated PVB19 infection, whereas 20% (n: 7) cases had coinfection with PVB19 and other viruses. Total and direct bilirubin, AST, and ALT values were significantly higher in patients with coinfection than in PVB19 infection alone, whereas synthetic functions (INR, serum albumin), complications and mortality were similar between the two groups. PVB19 hepatitis was associated with high rates of extrahepatic complications such as HLH, AA, AKI, and myocarditis in 25% cases and mortality of 20% predominantly in those with ALF.
The population known to be at the greatest risk of infection and hepatitis by PVB19 includes immunocompromised patients, transplant recipients, and individuals with an underlying hemolytic disorder.8 Hepatic involvement in healthy individuals is an uncommon but important cause of significant hepatic injury causing AVH, ALF, or ACLF.5,6,9, 10, 11, 12, 13 PVB19 infection is more frequent in younger than in older ones, and the same was shown in a large population-based seroepidemiological study from Serbia.24
In a study of 129 adults with non-A-E hepatitis, PVB19 was detected in 3 (2.3%) cases, similar to our findings.6 Literature about PVB19-related AVH in children is available mostly as case reports and small case series, probably due to lack of suspicion and testing for this infection as a cause of acute hepatitis.9,10
PVB19 infection–related ALF has been reported in children, mostly as case reports or small series.13,25, 26, 27, 28, 29, 30, 31, 32 In a retrospective analysis of 583 pediatric ALF cases across 16 pediatric liver transplant units in the United States of America (USA), 2.6% had PVB19 infection.26 Schwarz et al studied 860 children with nonacetaminophen ALF. Of these, only 260 cases were tested for PVB19, with 12 (4.6%) being positive.27 This study also highlighted that routine viral testing for determining etiology in pediatric ALF is often incomplete. Another multicenter study by Narkewicz et al, evaluating 1144 pediatric ALF cases, has reported other viruses (PVB19, EBV, adenovirus) to be causing ALF in 3.7% cases. The exact number of PVB19 cases has not been mentioned.28 In an Indian study by Alam et al, PVB19 was the etiology in 3 of 109 (2.8%) of PALF cases, similar to our findings.29
In a cohort of 26 ALF cases in children studied by Dwivedi et al, 19 cases had PVB19 (isolated PVB19- 6 [31.5%], coinfection with other hepatotropic viruses [HAV: 3, HBV: 6, HCV: 2, HEV + HAV: 2] in 13 [68.4%] cases). Another 7 cases with infection by hepatotropic viruses (HBV: 3, HAV: 2, HEV: 2) was taken for comparison.25 Dwivedi et al showed that ALF patients with coinfection had higher bilirubin, alanine aminotransferase, or aspartate aminotransferase than those with ALF due to PVB19 alone (n=6) or hepatotropic viruses alone (n=7: HAV: 1, HEV: 1, HBV: 3, HCV: 2), similar to our findings. PVB19 possibly causes greater injury to hepatocytes by producing a synergistic effect when present along with other hepatotropic viruses.8,25 Although children with coinfection had higher mortality than those with isolated PVB19-related ALF in their study, we did not find a significant difference in complications or mortality between these two groups. The reason for this difference is unclear and needs larger studies.
PVB19 has also been shown to be the acute insult in ACLF cases, as was found in five of our cases.33,34 Timely diagnosis and treatment with IVIG, along with therapy for the underlying CLD was helpful in improving cytopenia and liver functions.34
HLH is a hyperinflammatory condition characterized by fever, hepatosplenomegaly, pancytopenia, and phagocytosis of erythrocytes, leukocytes, platelets, and their precursors by macrophages in bone marrow and other tissues.20 PVB19 is one of the viruses implicated to cause secondary HLH, as was seen in 14% of our cases.35,36 CD8+ and CD4+ T-cell activation by PVB19 triggers marked production of tumor necrosis factor-α, a key factor in histiocytic activation as well as hepatic injury.8 PVB19-related HLH usually has a favorable prognosis.35 Shirono et al, studied 7 adults with PVB19-related HLH and showed that 85.7% (6/7) patients recovered either spontaneously (5/7) or after methylprednisolone (1/7), and only 14.5% (1/7) died despite immunosuppression.35 In another study of two children with PVB19-related HLH receiving immunosuppressive therapy with methylprednisolone and tenoposide, one child responded, whereas the other child died.36 In our cohort, HLH responded to immunosuppressive therapy in two of the 3 cases, which is similar to others.
Hepatitis-associated aplastic anemia is a distinct variant of acquired AA, in which an acute attack of hepatitis culminates in marrow failure and pancytopenia.37 There have been case reports of AA caused by PVB19 in immunocompetent children, as was seen in 2 children of our cohort.38, 39, 40 The myelotoxic effect in PVB19 infections is thought to be due to increased circulating cytotoxic CD8+ T cells and interferon-γ secretion by these cells that causes damage to the hepatocytes also.8,40 This myelosuppression usually resolves after viral clearance by neutralizing antibodies against PVB19 with simultaneous improvement in cell counts, though it may occasionally need treatment.9,39 PVB19-related AA is a dreaded but treatable complication with good outcome, as was seen in both our cases with AA.39,40
Anemia in AVH or virus-related ALF is usually due to coagulopathy-related bleeding, intravascular hemolysis with underlying glucose-6-phosphate dehydrogenase deficiency, or autoimmune hemolytic anemia triggered by the virus or marrow suppression.38 In AVH or ALF caused by hepatitis A, B, and E, anemia is not a common finding without a history of blood loss.23,41 On the contrary, in PVB19 infection, anemia is a predominant finding as this virus has a predilection for infecting the erythrocyte progenitor cells.2 Majority (85%) of our PVB19 cases had anemia, with a median hemoglobin of 8 gm/dL (IQR: 6.3–10.1) as compared to only 19% having anemia with median hemoglobin of 9.8 gm/dL (IQR: 8.6–10.7) in hepatitis A–, E–, or B–related AVH.23 Thus, presence of unexplained anemia in a case with AVH is a pointer toward PVB19 infection.
PVB19-related AVH usually shows complete and spontaneous remission, similar to our AVH cases.10,42 The poor outcome in both our children with AVH was due to the extrahepatic complications of HLH and myocarditis in one case each. There is no specific treatment for PVB19 infection. IVIG is often recommended in individuals with severe acute disease (HLH, bone marrow suppression, and myocarditis) or chronic infection.43 It has been used in patients with PVB19 hepatitis also with variable results.43, 44, 45, 46 A response rate of ∼80% was demonstrated by Crabol et al in PVB19-related bone marrow suppression or HLH, similar to our findings (response in 67% of cases).45 However, the response to IVIG therapy is poor in patients with PVB19-related myocarditis, similar to our case.46
Our study has certain limitations. It was a retrospective analysis with the inherent problem of missing data. Second, as not all cases with acute hepatitis were tested for PVB19, especially in the sequential testing approach, so some cases of coinfection might not have been diagnosed. Also, we could have missed the milder or anicteric forms of PVB19-related hepatitis due to a lack of suspicion and appropriate testing. Furthermore, we have not tested for the entire extended panel of viral etiology such as adenovirus, human herpes virus-6, etc. due to financial constraints.
The other limitations are related to the serological assays for PVB19. Although the commercial ELISA kits used for IgM testing have a high sensitivity (97.4%–100%) and specificity (99.2%–100%), there is a small possibility that IgM may be false positive in patients with other viral infections (enterovirus, HSV, EBV, CMV, and rubella virus).47 However, there are no studies showing cross reactivity with HAV and HEV.48 Furthermore, we have not done PVB-PCR in our cases, which is important for diagnosis of PVB19 infection in immunocompromised patients and the staging of infection in immunocompetent individuals. Using a combination of molecular (quantitative PCR) and serological (EIA) data may prove useful in differentiating recent from past infection.49
We have not done a detailed work-up for underlying immunodeficiency in our children, although none of them had any pointers toward the same. Lastly, as our hospital is a tertiary care center; patients with more severe symptoms are likely to form the major bulk of the study population, which may overestimate the true spectrum of hepatic involvement in PVB19 infections.
PVB19 is an uncommon but important cause of acute liver injury in the form of AVH, ALF, or the acute insult in ACLF in immunocompetent children. A high index of suspicion for PVB19 should be raised in patients with ALI and extra-hepatic complications like myocarditis, AA or HLH or ALI in a young child. PVB19 testing should ideally be included in the initial etiological panel of AVH, ALF, and ACLF in children before labeling them as “true” indeterminate.
Credit authorship contribution statement
AS: Data collection, analysis and interpretation. Literature review and drafting of the manuscript; ASr: Conception and design of the study, data analysis and interpretation, critical revision of the manuscript; SSP: Data collection, interpretation of the data, critical revision of the manuscript; MSS, UP, PM: Supervision of the study, data analysis, critical revision of the manuscript.
Declaration of competing interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Funding
This study received no funding.
Ethical statement
The study was performed in a manner to conform with Helsinki Declaration of 1975, as revised in 2000 and 2008, concerning human and Animal Rights.
Data availability
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
Prior presentation
These data were presented at Asia Pacific Digestive Week, held at Bangkok, Thailand, December 6–9, 2023.
Declaration of competing interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References
- 1.Brown K.E., Young N.S. The simian parvoviruses. Rev Med Virol. 1997;7:211–218. doi: 10.1002/(sici)1099-1654(199712)7:4<211::aid-rmv204>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
- 2.Young N.S., Brown K.E. Mechanisms of disease: PVB19. N Engl J Med. 2004;350:586–597. doi: 10.1056/NEJMra030840. [DOI] [PubMed] [Google Scholar]
- 3.Chorba T., Coccia P., Holman R.C. The role of PVB19 in aplastic crisis and erythema infectiosum (fifth disease) JID (J Infect Dis) 1986;154:383–393. doi: 10.1093/infdis/154.3.383. [DOI] [PubMed] [Google Scholar]
- 4.Broliden K., Tolfvenstam T., Norbeck O. Clinical aspects of PVB19 infection. J Intern Med. 2006;260:285–304. doi: 10.1111/j.1365-2796.2006.01697.x. [DOI] [PubMed] [Google Scholar]
- 5.Hatakka A., Klein J., He R., Piper J., Tam E., Walkty A. Acute hepatitis as a manifestation of PVB19 infection. J Clin Microbiol. 2011;49:3422–3424. doi: 10.1128/JCM.00575-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Pinho J.R., Alves V.A., Vieira A.F., et al. Detection of human PVB19 in a patient with hepatitis. Detection of human PVB19 in a patient with hepatitis. Braz J Med Biol Res. 2001;34:1131–1138. doi: 10.1590/s0100-879x2001000900005. [DOI] [PubMed] [Google Scholar]
- 7.Arista S., De Grazia S., Di Marco V., Di Stefano R., Craxì A. PVB19 and “cryptogenic” chronic hepatitis. J Hepatol. 2003;38:375–376. doi: 10.1016/s0168-8278(02)00416-6. [DOI] [PubMed] [Google Scholar]
- 8.Bihari C., Rastogi A., Saxena P., et al. PVB19 associated hepatitis. Hepat Res Treat. 2013;2013 doi: 10.1155/2013/472027. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Yoto Y., Kudoh T., Haseyama K., Suzuki N., Chiba S. Human parvovirus B19 infection associated with acute hepatitis. Lancet. 1996;347:868–869. doi: 10.1016/s0140-6736(96)91348-3. [DOI] [PubMed] [Google Scholar]
- 10.Koliou M., Karaoli E., Soteriades E.S., Pavlides S., Bashiardes S., Christodoulou C. Acute hepatitis and myositis associated with Erythema infectiosum by PVB19 in an adolescent. BMC Pediatr. 2014;14:6. doi: 10.1186/1471-2431-14-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Sokal E.M., Melchior M., Cornu C., et al. Acute PVB19 infection associated with fulminant hepatitis of favourable prognosis in young children. Lancet. 1998;352:1739–1741. doi: 10.1016/S0140-6736(98)06165-0. [DOI] [PubMed] [Google Scholar]
- 12.Langnas A.N., Markin R.S., Cattral M.S., Naides S.J. Parvovirus B19 as a possible causative agent of fulminant liver failure and associated aplastic anemia. Hepatology. 1995;22:1661–1665. [PubMed] [Google Scholar]
- 13.Islek A., Keskin H., Agın M., Aksungur N., Korkut E., Ozturk G. Parvovirus B19 infection as a rare cause of fulminant liver failure: a case report. Transplant Proc. 2019;51:1169–1171. doi: 10.1016/j.transproceed.2019.01.084. [DOI] [PubMed] [Google Scholar]
- 14.Squires RH Jr, Shneider B.L., Bucuvalas J., et al. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr. 2006;148:652–658. doi: 10.1016/j.jpeds.2005.12.051. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Sarin S.K., Choudhury A., Sharma M.K., et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update [published correction appears in Hepatol Int. 2019 Nov;13(6):826-828] Hepatol Int. 2019;13:353–390. doi: 10.1007/s12072-019-09946-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Mieli-Vergani G., Vergani D., Baumann U., et al. Diagnosis and management of pediatric autoimmune liver disease: ESPGHAN hepatology committee position statement. J Pediatr Gastroenterol Nutr. 2018;66:345–360. doi: 10.1097/MPG.0000000000001801. [DOI] [PubMed] [Google Scholar]
- 17.Socha P., Janczyk W., Dhawan A., et al. Wilson's disease in children: a position paper by the hepatology committee of the European society for paediatric Gastroenterology, hepatology and nutrition. J Pediatr Gastroenterol Nutr. 2018;66:334–344. doi: 10.1097/MPG.0000000000001787. [DOI] [PubMed] [Google Scholar]
- 18.Valla D.C. The diagnosis and management of the Budd-Chiari syndrome: consensus and controversies. Hepatology. 2003;38:793–803. doi: 10.1053/jhep.2003.50415. [DOI] [PubMed] [Google Scholar]
- 19.Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1–138. [Google Scholar]
- 20.Henter J.I., Horne A., Aricó M., et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124. doi: 10.1002/pbc.21039. [DOI] [PubMed] [Google Scholar]
- 21.Marsh J.C., Ball S.E., Cavenagh J., et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009;147:43–70. doi: 10.1111/j.1365-2141.2009.07842.x. [DOI] [PubMed] [Google Scholar]
- 22.Caforio A.L., Pankuweit S., Arbustini E., et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34:2636–2648. doi: 10.1093/eurheartj/eht210. [DOI] [PubMed] [Google Scholar]
- 23.Samanta A., Poddar U., Sen Sarma M., Srivastava A., Yachha S.K., Mishra P. Persistent fever in acute hepatitis: think beyond acute viral hepatitis. Inf Disp. 2024;56:476–483. doi: 10.1080/23744235.2024.2325568. [DOI] [PubMed] [Google Scholar]
- 24.Vuković V., Patić A., Ristić M., Kovačević G., Hrnjaković Cvjetković I., Petrović V. Seroepidemiology of human parvovirus B19 infection among the population of vojvodina, Serbia, over a 16-year period (2008-2023) Viruses. 2024;16:180. doi: 10.3390/v16020180. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Dwivedi M., Manocha H., Tiwari S., Tripathi G., Dhole T.N. Coinfection of PVB19 with other hepatitis viruses leading to fulminant hepatitis of unfavorable outcome in children. Pediatr Infect Dis J. 2009;28:649–650. doi: 10.1097/INF.0b013e318198d05c. [DOI] [PubMed] [Google Scholar]
- 26.Kulkarni S., Perez C., Pichardo C., et al. Use of Pediatric Health Information System database to study the trends in the incidence, management, etiology, and outcomes due to pediatric acute liver failure in the United States from 2008 to 2013. Pediatr Transplant. 2015;19:888–895. doi: 10.1111/petr.12596. [DOI] [PubMed] [Google Scholar]
- 27.Schwarz K.B., Dell Olio D., Lobritto S.J., et al. Analysis of viral testing in non-acetaminophen pediatric acute liver failure. J Pediatr Gastroenterol Nutr. 2014;59:616–623. doi: 10.1097/MPG.0000000000000512. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Narkewicz M.R., Horslen S., Hardison R.M., et al. A learning collaborative approach increases specificity of diagnosis of acute liver failure in pediatric patients. Clin Gastroenterol Hepatol. 2018;16:1801–1810.e3. doi: 10.1016/j.cgh.2018.04.050. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Alam S., Khanna R., Sood V., Lal B.B., Rawat D. Profile and outcome of first 109 cases of paediatric acute liver failure at a specialized paediatric liver unit in India. Liver Int. 2017;37:1508–1514. doi: 10.1111/liv.13370. [DOI] [PubMed] [Google Scholar]
- 30.Singh D.P., Agarwal S., Singh R., Nandan D., Gupta A. Therapeutic plasma exchange in parvovirus B19-induced acute hepatic failure. Indian J Crit Care Med. 2020;24:361–362. doi: 10.5005/jp-journals-10071-23421. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Dutta U., Mittal S., Ratho R.K., Das A. Acute liver failure and severe hemophagocytosis secondary to parvovirus B19 infection. Indian J Gastroenterol. 2005;24:118–119. [PubMed] [Google Scholar]
- 32.Kishore J., Sen M. Parvovirus B19-induced thrombocytopenia and anemia in a child with fatal fulminant hepatic failure coinfected with hepatitis A and E viruses. J Trop Pediatr. 2009;55:335–337. doi: 10.1093/tropej/fmp004. [DOI] [PubMed] [Google Scholar]
- 33.Sharma S., Lal S.B., Sachdeva M., Bhatia A., Varma N. Role of granulocyte colony stimulating factor on the short-term outcome of children with acute on chronic liver failure. J Clin Exp Hepatol. 2020;10:201–210. doi: 10.1016/j.jceh.2019.10.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Shiraishi A., Hoshina T., Ihara K., Doi T., Ohga S., Hara T. Acute liver failure as the initial manifestation of Wilson disease triggered by human PVB19 infection. Pediatr Infect Dis J. 2012;31:103–104. doi: 10.1097/INF.0b013e31823662ee. [DOI] [PubMed] [Google Scholar]
- 35.Shirono K., Tsuda H. PVB19-associated haemophagocytic syndrome in healthy adults. Br J Haematol. 1995;89:923–926. doi: 10.1111/j.1365-2141.1995.tb08440.x. [DOI] [PubMed] [Google Scholar]
- 36.Henter J.I., Ehrnst A., Andersson J., Elinder G. Familial hemophagocytic lymphohistiocytosis and viral infections. Acta Paediatr. 1993;82:369–372. doi: 10.1111/j.1651-2227.1993.tb12699.x. [DOI] [PubMed] [Google Scholar]
- 37.Pardi D.S., Romero Y., Mertz L.E., Douglas D.D. Hepatitis-associated aplastic anemia and acute PVB19 infection: a report of two cases and a review of the literature. Am J Gastroenterol. 1998;93:468–470. doi: 10.1111/j.1572-0241.1998.468_1.x. [DOI] [PubMed] [Google Scholar]
- 38.Lugassy G. Chronic pure red cell aplasia associated with PVB19 infection in an immunocompetent patient. Am J Hematol. 2002;71:238–239. doi: 10.1002/ajh.10241. [DOI] [PubMed] [Google Scholar]
- 39.Tung J., Hadzic N., Layton M., et al. Bone marrow failure in children with acute liver failure. J Pediatr Gastroenterol Nutr. 2000;31:557–561. doi: 10.1097/00005176-200011000-00019. [DOI] [PubMed] [Google Scholar]
- 40.Brown K.E., Young N.S. Parvoviruses and bone marrow failure. Stem Cell. 1996;14:151–163. doi: 10.1002/stem.140151. [DOI] [PubMed] [Google Scholar]
- 41.Desai H.D., Ansari A.A.Z., Makwana D., Jadeja D.M., Gusani J. Clinical-biochemical profile and etiology of acute viral hepatitis in hospitalized young adults at tertiary care center. J Fam Med Prim Care. 2020;9:247–252. doi: 10.4103/jfmpc.jfmpc_727_19. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Tesapirat L., Wanlapakorn N., Chieochansin T., Poovorawan Y. PVB19 infection presenting as acute hepatitis and transient anemia in a previously healthy child. Southeast Asian J Trop Med Publ Health. 2015;46:226–230. [PubMed] [Google Scholar]
- 43.Al-Abdwani R.M., Khamis F.A., Balkhair A., Sacharia M., Wali Y.A. A child with human PVB19 infection induced aplastic anemia and acute hepatitis: effectiveness of immunosuppressive therapy. Pediatr Hematol Oncol. 2008;25:699–703. doi: 10.1080/08880010802341724. [DOI] [PubMed] [Google Scholar]
- 44.Dame C., Hasan C., Bode U., Eis-Hübinger A.M. Acute liver disease and aplastic anemia associated with the persistence of B19 DNA in liver and bone marrow. Pediatr Pathol Mol Med. 2002;21:25–29. doi: 10.1080/pdp.21.1.25.29. [DOI] [PubMed] [Google Scholar]
- 45.Crabol Y., Terrier B., Rozenberg F., et al. Intravenous immunoglobulin therapy for pure red cell aplasia related to human PVB19 infection: a retrospective study of 10 patients and review of the literature. Clin Infect Dis. 2013;56:968–977. doi: 10.1093/cid/cis1046. [DOI] [PubMed] [Google Scholar]
- 46.Izquierdo-Blasco J., Salcedo Allende M.T., Codina Grau M.G., Gran F., Martínez Sáez E., Balcells J. Parvovirus B19 myocarditis: looking beyond the heart. Pediatr Dev Pathol. 2020;23:158–162. doi: 10.1177/1093526619865641. [DOI] [PubMed] [Google Scholar]
- 47.Tolfvenstam T., Ruden U., Broliden K. Evaluation of serological assays for identification of parvovirus b19 immunoglobulin m. Clin Diagn Lab Immunol. 1996;3:147–150. doi: 10.1128/cdli.3.2.147-150.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Peterlana D., Puccetti A., Corrocher R., Lunardi C. Serologic and molecular detection of human Parvovirus B19 infection. Clin Chim Acta. 2006;372:14–23. doi: 10.1016/j.cca.2006.04.018. [DOI] [PubMed] [Google Scholar]
- 49.Maple P.A., Hedman L., Dhanilall P., et al. Identification of past and recent parvovirus B19 infection in immunocompetent individuals by quantitative PCR and enzyme immunoassays: a dual-laboratory study. J Clin Microbiol. 2014;52:947–956. doi: 10.1128/JCM.02613-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

